NCT06653153

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,400 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 55 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	Remternetug	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2024-10-24
• Primary completion: 2029-04-01
• Completion: 2030-10-01
• First posted: 2024-10-22
• Last updated: 2025-11-20

Locations

262 sites across 10 countries: United States, Australia, Canada, China, Japan, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom

Regulatory

• FDA-regulated drug study